Acadia Healthcare (NASDAQ:ACHC) Earns Buy Rating from Analysts at Guggenheim

Equities researchers at Guggenheim started coverage on shares of Acadia Healthcare (NASDAQ:ACHC) in a research note issued to investors on Wednesday, Marketbeat Ratings reports. The firm set a “buy” rating and a $36.00 price target on the stock. Guggenheim’s price target suggests a potential upside of 32.94% from the company’s current price.

A number of other brokerages also recently issued reports on ACHC. Deutsche Bank Aktiengesellschaft upgraded shares of Acadia Healthcare from a “hold” rating to a “buy” rating and raised their price target for the stock from $45.00 to $75.00 in a report on Thursday, December 12th. Royal Bank of Canada reduced their target price on Acadia Healthcare from $64.00 to $43.00 and set an “outperform” rating on the stock in a research report on Monday, March 3rd. StockNews.com cut Acadia Healthcare from a “hold” rating to a “sell” rating in a report on Monday, January 6th. TD Cowen reduced their price objective on shares of Acadia Healthcare from $70.00 to $66.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Finally, Mizuho dropped their price target on shares of Acadia Healthcare from $48.00 to $37.00 and set a “neutral” rating for the company in a research report on Tuesday, March 25th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $50.39.

Acadia Healthcare Trading Down 6.9 %

Shares of ACHC opened at $27.08 on Wednesday. Acadia Healthcare has a 12-month low of $25.41 and a 12-month high of $82.41. The firm has a market capitalization of $2.52 billion, a P/E ratio of 8.88, a P/E/G ratio of 1.46 and a beta of 1.13. The firm has a 50-day moving average price of $33.60 and a 200 day moving average price of $41.53. The company has a current ratio of 1.07, a quick ratio of 1.07 and a debt-to-equity ratio of 0.60.

Institutional Trading of Acadia Healthcare

Several hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC increased its stake in Acadia Healthcare by 7,291.8% during the 1st quarter. GAMMA Investing LLC now owns 176,220 shares of the company’s stock worth $5,812,000 after buying an additional 173,836 shares during the period. Phocas Financial Corp. increased its position in shares of Acadia Healthcare by 30.6% during the fourth quarter. Phocas Financial Corp. now owns 94,320 shares of the company’s stock worth $3,740,000 after acquiring an additional 22,095 shares during the period. Public Employees Retirement System of Ohio acquired a new stake in shares of Acadia Healthcare in the fourth quarter valued at $1,293,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Acadia Healthcare by 22.0% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 313,709 shares of the company’s stock valued at $12,439,000 after purchasing an additional 56,647 shares during the period. Finally, Voloridge Investment Management LLC acquired a new position in Acadia Healthcare during the 4th quarter worth $15,770,000.

Acadia Healthcare Company Profile

Acadia Healthcare Company, Inc provides behavioral healthcare services in the United States and Puerto Rico. The company develops and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, comprehensive treatment centers, and residential treatment centers, as well as facilities offering outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities.